loading page

Comparative efficacy and safety of antihypertensive agents in preeclampsia and gestational hypertension uncontrolled and their long-term effects on offspring
  • +6
  • Cai Xiaotong,
  • Jun Zhao,
  • Xin Yang,
  • Wenhai Fu,
  • Benyue Liu,
  • Yuqing Li,
  • Jiying Wen,
  • Haibin Hu,
  • Duanling Tan
Cai Xiaotong
Guangzhou Medical College
Author Profile
Jun Zhao
Department of Obstetrics and Gynecology, Guangdong province maternity and child care hospital
Author Profile
Xin Yang
Key Laboratory of Molecular Target & Clinical Pharmacology and the State & NMPA Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences & The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou 511436, China
Author Profile
Wenhai Fu
The First Affiliated Hospital of Guangzhou Medical University, China National Center for Respiratory Medicine, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease
Author Profile
Benyue Liu
Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, China
Author Profile
Yuqing Li
Guangzhou Medical University
Author Profile
Jiying Wen
Department of Obstetrics, Guangdong Women and Children Hospital, Guangzhou, Guangdong 510010, China
Author Profile
Haibin Hu
Department of Obstetrics, Guangdong Women and Children Hospital, Guangzhou, Guangdong 510010, China
Author Profile
Duanling Tan
Key Laboratory of Molecular Target & Clinical Pharmacology and the State & NMPA Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences & The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou 511436, China
Author Profile

Abstract

Background: Hypertensive disorder of pregnancy (HDP), a common obstetric complication that seriously threatens maternal and infant health. The current clinical treatment drugs include methyldopa, calcium channel blockers, etc. In order to provide evidence-based medicine for the treatment and medication of gestational hypertension, this study compared the efficacy and safety of different drugs in the treatment of gestational hypertension through network meta-analysis. Methods: Search and select relevant articles in the published and unpublished available data from Controlled Trials, PsycINFO, CINAHL,, etc. To assess the efficacy and safety of HDP treatment, 4 primary outcomes [SBP, DBP, perinatal fetal deaths, and NICU cases] and 9 secondary outcomes were selected. Results: 50 articles with 8212 participants were included. Low molecular weight heparin (LMH), Labetalol + LMH and Labetalol + Methyldopa can reduce DBP, and Ambrisentan + Methyldopa can prevent the occurrence of severe hypertension. Methyldopa and Atenolol were associated with lower rates of preterm birth, and Nifedipine, Methyldopa as well as Labetalol reduced the incidence of placental abruption. Ambrisentan + Nifedipine, Methyldopa, Labetalol + Nimodipine, Labetalol + LMH, Labetalol and LMH significantly reduced the incidence of postpartum complications. Magnesium sulfate (SM) and SM+ LMH can prolong the mean gestational age, LMH and Kethyldopa can reduce perinatal fetal death. Conclusions: LMH, labetalol, Methyldopa, labetalol in combination with LMH, and labetalol in combination with Methyldopa have better efficacy and safety.